Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Bone Fracture - Overview Bone Fracture - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Bone Fracture - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Bone Fracture - Companies Involved in Therapeutics Development American Gene Technologies International Inc BiologicsMD Inc Biopharm GmbH Bone Therapeutics SA Cellmid Ltd Chrysalis BioTherapeutics Inc Entera Bio Ltd Escape Therapeutics Inc ethris GmbH Hemostemix Inc Kuros Biosciences AG Laboratorios SALVAT SA Novartis AG Pluristem Therapeutics Inc TissueGene Inc Viking Therapeutics Inc Bone Fracture - Drug Profiles ALLOB - Drug Profile Product Description Mechanism Of Action R&D Progress BCP-01 - Drug Profile Product Description Mechanism Of Action R&D Progress bimagrumab - Drug Profile Product Description Mechanism Of Action R&D Progress BMD-1221 - Drug Profile Product Description Mechanism Of Action R&D Progress cannabidiol - Drug Profile Product Description Mechanism Of Action R&D Progress Cyndacel-M - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for Bone Fracture - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for Bone Fracture - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile Product Description Mechanism Of Action R&D Progress HCSVT-1001 - Drug Profile Product Description Mechanism Of Action R&D Progress KAL-436 - Drug Profile Product Description Mechanism Of Action R&D Progress KAL-439 - Drug Profile Product Description Mechanism Of Action R&D Progress KUR-111 - Drug Profile Product Description Mechanism Of Action R&D Progress KUR-113 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile Product Description Mechanism Of Action R&D Progress OsteoStem - Drug Profile Product Description Mechanism Of Action R&D Progress PLX-PAD - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Peptide to Agonize PTH1R for Bone Fracture - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress rusalatide acetate - Drug Profile Product Description Mechanism Of Action R&D Progress S-008399 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile Product Description Mechanism Of Action R&D Progress TG-B - Drug Profile Product Description Mechanism Of Action R&D Progress VK-5211 - Drug Profile Product Description Mechanism Of Action R&D Progress Bone Fracture - Dormant Projects Bone Fracture - Discontinued Products Bone Fracture - Product Development Milestones Featured News & Press Releases Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB Dec 12, 2017: Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture Nov 22, 2017: Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study Oct 02, 2017: $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells Sep 26, 2017: Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study Sep 05, 2017: Pluristem Therapeutics: $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016 Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Bone Fracture, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Universities/Institutes, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Bone Fracture - Pipeline by American Gene Technologies International Inc, H1 2018 Bone Fracture - Pipeline by BiologicsMD Inc, H1 2018 Bone Fracture - Pipeline by Biopharm GmbH, H1 2018 Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2018 Bone Fracture - Pipeline by Cellmid Ltd, H1 2018 Bone Fracture - Pipeline by Chrysalis BioTherapeutics Inc, H1 2018 Bone Fracture - Pipeline by Entera Bio Ltd, H1 2018 Bone Fracture - Pipeline by Escape Therapeutics Inc, H1 2018 Bone Fracture - Pipeline by ethris GmbH, H1 2018 Bone Fracture - Pipeline by Hemostemix Inc, H1 2018 Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2018 Bone Fracture - Pipeline by Laboratorios SALVAT SA, H1 2018 Bone Fracture - Pipeline by Novartis AG, H1 2018 Bone Fracture - Pipeline by Pluristem Therapeutics Inc, H1 2018 Bone Fracture - Pipeline by TissueGene Inc, H1 2018 Bone Fracture - Pipeline by Viking Therapeutics Inc, H1 2018 Bone Fracture - Dormant Projects, H1 2018 Bone Fracture - Dormant Projects, H1 2018 (Contd..1), H1 2018 Bone Fracture - Discontinued Products, H1 2018List of Figures Number of Products under Development for Bone Fracture, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Number of Products by Top 10 Targets, H1 2018 Number of Products by Stage and Top 10 Targets, H1 2018 Number of Products by Top 10 Mechanism of Actions, H1 2018 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Top 10 Molecule Types, H1 2018 Number of Products by Stage and Top 10 Molecule Types, H1 2018